Cytosin-Arabinosid

AIDS-related Diffuse Mixed Cell Lymphoma

Fred Hutchinson Cancer CenterN/ADormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the AIDS-related Diffuse Mixed Cell Lymphoma cohort.

Asset / Sponsor	Phase	Rating
VINCRISTINE SULFATE AIDS Malignancy Consortium	Phase 2	BB
Inno-206 AIDS Malignancy Consortium	Phase 2	B
Hycamtin National Cancer Institute (NCI)	Phase 2	B
Cyclophosphamide AIDS Malignancy Consortium	Phase 2	B
Lomustine AIDS Malignancy Consortium	Phase 2	B

View all 22 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant

A

Indicative ·

82 / 100

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.